Addison Kenneth J, Morse John, Robichaud Annette, Daines Michael O, Ledford Julie G
Department of Medicine, University of Arizona, Tucson, Arizona, USA.
SCIREQ Inc., Montreal, Québec, Canada.
J Infect Pulm Dis. 2017 Mar;3(1). doi: 10.16966/2470-3176.120. Epub 2017 Feb 3.
The incidence and severity of asthma continue to rise worldwide. β-agonists are the most commonly prescribed therapeutic for asthma management but have less efficacy for some subsets of asthmatic patients and there are concerns surrounding the side effects from their long-term persistent use. The demand to develop novel asthma therapeutics highlights the need for a standardized approach to effectively screen and test potential bronchoprotective compounds using relevant animal models. Here we describe a validated method of testing potential therapeutic compounds for their fast-acting efficacy during the midst of an induced bronchoconstriction in a house dust mite challenged animal model.
全球范围内,哮喘的发病率和严重程度持续上升。β-受体激动剂是哮喘治疗中最常用的药物,但对某些哮喘患者亚组疗效较差,且长期持续使用会产生副作用,令人担忧。开发新型哮喘治疗药物的需求凸显了采用标准化方法,利用相关动物模型有效筛选和测试潜在支气管保护化合物的必要性。在此,我们描述了一种经过验证的方法,用于在屋尘螨激发的动物模型中,测试潜在治疗化合物在诱发支气管收缩过程中的速效疗效。